NO20044442L - Fosfatprodroger av fluoroksindoler - Google Patents

Fosfatprodroger av fluoroksindoler

Info

Publication number
NO20044442L
NO20044442L NO20044442A NO20044442A NO20044442L NO 20044442 L NO20044442 L NO 20044442L NO 20044442 A NO20044442 A NO 20044442A NO 20044442 A NO20044442 A NO 20044442A NO 20044442 L NO20044442 L NO 20044442L
Authority
NO
Norway
Prior art keywords
oxindoles
fluoro
phosphate prodrugs
enantiomer
racemate
Prior art date
Application number
NO20044442A
Other languages
English (en)
Inventor
John E Starrett
Piyasena Hewawasam
Kevin W Gillman
William D Schmitz
Omar D Lopez
David P Provencal
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20044442L publication Critical patent/NO20044442L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer nye fosfatderivater som har den generelle formel (1), hvor den bølgete bindingen (~~) representerer racematet, (R)-enantiomeren eller (S)-enantiomeren og A, B, R\ R^, R^, R'', m og n er som definert her. Eller et ikke-toksisk farmasøytisk akseptabelt salt eller solvat derav, og er anvendelige ved behandling av lidelser som reagerer på åpning av kaliumkanaler.
NO20044442A 2002-03-20 2004-10-19 Fosfatprodroger av fluoroksindoler NO20044442L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36601002P 2002-03-20 2002-03-20
PCT/US2003/008613 WO2003080047A1 (en) 2002-03-20 2003-03-20 Phosphate prodrugs of fluorooxindoles

Publications (1)

Publication Number Publication Date
NO20044442L true NO20044442L (no) 2004-10-19

Family

ID=28454740

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20044442A NO20044442L (no) 2002-03-20 2004-10-19 Fosfatprodroger av fluoroksindoler

Country Status (21)

Country Link
US (1) US6930100B2 (no)
EP (1) EP1485085A4 (no)
JP (1) JP4359150B2 (no)
KR (1) KR100951499B1 (no)
CN (1) CN100384820C (no)
BR (1) BR0308737A (no)
CA (1) CA2479256A1 (no)
CO (1) CO5611143A2 (no)
GE (1) GEP20074230B (no)
HR (1) HRP20040853A2 (no)
IL (2) IL164022A0 (no)
IS (1) IS7456A (no)
MX (1) MXPA04008999A (no)
NO (1) NO20044442L (no)
NZ (1) NZ535365A (no)
PL (1) PL372413A1 (no)
RS (1) RS81904A (no)
RU (1) RU2312857C2 (no)
UA (1) UA77296C2 (no)
WO (1) WO2003080047A1 (no)
ZA (1) ZA200407337B (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
EP1534286B1 (en) 2002-07-29 2009-12-09 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US6916937B2 (en) * 2003-02-03 2005-07-12 Bristol-Myers Squibb Company Carbohydrate prodrugs of fluorooxindoles
US7169803B2 (en) * 2004-03-15 2007-01-30 Bristol-Myers Squibb Company N-substituted prodrugs of fluorooxindoles
US7253167B2 (en) 2004-06-30 2007-08-07 Bristol-Myers Squibb Company Tricyclic-heteroaryl compounds useful as kinase inhibitors
CA2591948C (en) 2005-01-19 2013-11-12 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US8227455B2 (en) * 2005-04-18 2012-07-24 Rigel Pharmaceuticals, Inc. Methods of treating cell proliferative disorders
US20090114877A1 (en) * 2005-09-13 2009-05-07 Eisai R&D Management Co., Ltd. Composition Containing Stability-Improved Chloromethyl Phosphate Derivatve and Process for Producing Same
TWI385169B (zh) 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd 經雜環取代之吡啶衍生物及含有彼之抗真菌劑
TW200841879A (en) 2007-04-27 2008-11-01 Eisai R&D Man Co Ltd Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same
US8513287B2 (en) * 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
CA2722536A1 (en) * 2008-02-05 2009-08-13 Merck & Co., Inc. Prodrugs of cgrp receptor antagonist
US8188119B2 (en) * 2008-10-24 2012-05-29 Eisai R&D Management Co., Ltd Pyridine derivatives substituted with heterocyclic ring and γ-glutamylamino group, and antifungal agents containing same
US8686009B2 (en) * 2009-06-25 2014-04-01 Alkermes Pharma Ireland Limited Prodrugs of NH-acidic compounds
RS56352B2 (sr) * 2009-06-25 2023-02-28 Alkermes Pharma Ireland Ltd Heterociklična jedinjenja za lečenje neuroloških i psiholoških poremećaja
ES2691671T3 (es) 2010-06-24 2018-11-28 Alkermes Pharma Ireland Limited Profármacos de compuestos NH-acídicos: derivados de éster, carbonato, carbamato y fosfonato
KR102443575B1 (ko) 2015-07-06 2022-09-16 길리애드 사이언시즈, 인코포레이티드 Cot 조정제 및 그의 사용 방법
WO2019136298A1 (en) 2018-01-05 2019-07-11 Cybrexa, Inc. Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
JP2021517164A (ja) * 2018-03-05 2021-07-15 テオン セラピューティクス，インク． アデノシン受容体アンタゴニストおよびその使用
EP3761983A1 (en) 2018-03-05 2021-01-13 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
TWI770527B (zh) 2019-06-14 2022-07-11 美商基利科學股份有限公司 Cot 調節劑及其使用方法
PE20220563A1 (es) 2019-07-10 2022-04-13 Cybrexa 2 Inc Conjugados peptidicos de citotoxinas como terapeuticos
CN114302744A (zh) 2019-07-10 2022-04-08 赛博克萨3公司 作为治疗剂的微管靶向剂的肽缀合物
KR20220160645A (ko) 2020-04-02 2022-12-06 길리애드 사이언시즈, 인코포레이티드 Cot 저해제 화합물의 제조 방법
EP3912625A1 (en) 2020-05-20 2021-11-24 Kaerus Bioscience Limited Novel maxi-k potassium channel openers for the treatment of fragile x associated disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234947A (en) 1991-11-07 1993-08-10 New York University Potassium channel activating compounds and methods of use thereof
US5187173A (en) * 1991-12-27 1993-02-16 Sterling Winthrop Inc. 2-saccharinylmethyl and 4,5,6,7-tetrahydro-2-saccharinylmethyl phosphates, phosphonates and phosphinates useful as proteolytic enzyme inhibitors and compositions and method of use thereof
US5565483A (en) * 1995-06-07 1996-10-15 Bristol-Myers Squibb Company 3-substituted oxindole derivatives as potassium channel modulators
CA2317008C (en) 1997-12-31 2009-01-20 The University Of Kansas Water soluble prodrugs of tertiary amine containing drugs and methods of making thereof
DK1056754T3 (da) * 1998-01-29 2004-02-16 Bristol Myers Squibb Co Phosphatderivater af diaryl-1,3,4-oxadiazolon

Also Published As

Publication number Publication date
ZA200407337B (en) 2006-02-22
CN1652769A (zh) 2005-08-10
BR0308737A (pt) 2005-01-11
NZ535365A (en) 2006-07-28
GEP20074230B (en) 2007-11-12
RU2004131201A (ru) 2005-05-10
WO2003080047A1 (en) 2003-10-02
KR20040106293A (ko) 2004-12-17
HRP20040853A2 (en) 2004-12-31
AU2003215017A1 (en) 2003-10-08
IS7456A (is) 2004-09-17
US6930100B2 (en) 2005-08-16
IL164022A0 (en) 2005-12-18
RS81904A (en) 2007-02-05
MXPA04008999A (es) 2004-12-07
EP1485085A1 (en) 2004-12-15
UA77296C2 (en) 2006-11-15
US20030195169A1 (en) 2003-10-16
IL164022A (en) 2008-04-13
CN100384820C (zh) 2008-04-30
CA2479256A1 (en) 2003-10-02
EP1485085A4 (en) 2007-03-14
JP2005526097A (ja) 2005-09-02
RU2312857C2 (ru) 2007-12-20
PL372413A1 (en) 2005-07-25
CO5611143A2 (es) 2006-02-28
KR100951499B1 (ko) 2010-04-07
JP4359150B2 (ja) 2009-11-04

Similar Documents

Publication Publication Date Title
NO20044442L (no) Fosfatprodroger av fluoroksindoler
ZA200600343B (en) Substituted 2-aminotetralin for the treatment of depression
WO2005042497A3 (en) Benzimidazoles useful as modulators of ion channels
NO20054852L (no) GFAT inhibitorer
NO20054880L (no) Azaspiroalkanderivater som inhibitorer av metallproeaser
NO20071719L (no) Pyridylinhibitorer for "hedgehog"-signalisering
NO20052699L (no) 4(fenylpiperazinyl-metyl)benzamid-derivater og deres anvendelse ved behandling av smerte og gastrointestinale lidelser.
HRP20090281T1 (en) 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases
WO2006005609A3 (de) Substituierte oxindol-derivate und diese enthaltende arzneimittel
NO20052698L (no) 4(fenylpiperazinyl-metyl)benzamid-derivater og deres anvendelse ved behandling av smerte og gasatrintestinale lidelser.
NO20062021L (no) Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika
NO20071137L (no) Nye piperidinderivater for behandling av depresjon
NO20052730L (no) Aminoalkosyindoler som 5-HT6-reseptorligander for behandling av CNS-lidelser
MY135218A (en) 2,6-quinolinyl and 2,6-naphthyl derivatives and their use in the treatment of vla-4 dependent diseases
HUP0303639A2 (hu) Új amlodipin-kamzilát és eljárás annak előállítására
NO20060718L (no) Substituerte tiofoner og deres anvendelse
NO20040881L (no) Orale antidiabetes midler.
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
RS20060280A (en) Novel keto-oxadiazole derivatives as cathepsin inhibitors
DE602004031410D1 (de) Inden derivate als pharmazeutika
NO20001781L (no) 3-amino-3-arylpropan-1-og lignende-derivater, deres fremstilling og anvendelse
NO20076000L (no) Aminosyrederivater
PT1056754E (pt) Derivados fosfatados de 1,3,4-oxadiazolona de diarilo
RS115804A (en) Pyrrolidine derivatives as oxytocin antagonists
NO20053805L (no) Diarylmetylindenpiperidinderivater, framgangsmate for fremstilling derav, og anvendelse derav

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application